Quick answer: A triple agonist is one molecule built to switch on three hormone receptors. The label sounds uniform, but the drugs behind it differ in which receptors they hit, how they are delivered, how far along they are and how solid the evidence is. Retatrutide has a peer-reviewed phase 3 paper. Most challengers have a short phase 1 or 2 result, or nothing public yet.
Ask PeptideBlog about any peptide
Research snapshot (as of Nov 12, 2026)
| Category | Current information |
|---|---|
| Topic | Investigational triple-receptor drugs for obesity and type 2 diabetes |
| Highest evidence in the field | Retatrutide: phase 3, published in the New England Journal of Medicine (Sept 29, 2026) |
| Challengers with peer-reviewed human data | UBT251 (three papers, Sept to Oct 2026) |
| Challengers with company-reported human data only | KAI-4729 / HRS-4729 (phase 1) |
| Registered trials, no public efficacy results found | MWN109, BI 3034701 |
| Preclinical or earliest-stage | ASC37, CT-G32, NBIP-1968 |
| Approved anywhere | None |
| Last reviewed | November 12, 2026 |
Why one label hides three different ideas
An agonist is a drug that switches a receptor on. Semaglutide switches on one (GLP-1). Tirzepatide switches on two (GLP-1 and GIP). “Triple” means three, and that is all the word promises.
In practice the field splits into groups:
- GLP-1, GIP and glucagon: retatrutide, UBT251, KAI-4729 (Kailera’s name; Hengrui’s code appears to be HRS-4729) and MWN109 are described this way. The glucagon arm is the third receptor. Glucagon is the hormone linked to energy expenditure, which is why the idea is attractive and why tolerability and balance matter.
- GLP-1, GIP and NPY2: Boehringer Ingelheim’s BI 3034701 has no glucagon arm. Its third receptor, NPY2, sits in a different appetite pathway. It entered phase 2 in July 2026 with no efficacy data public (BioPharm International, July 16, 2026).
- Four receptors: CT-G32 (SCO-940), which PB covered in the CT-G32 evidence audit, adds amylin to the incretin and glucagon targets. It is preclinical.
Putting these in one bucket is like calling a sedan, a pickup and a bus “vehicles with four wheels.” True, and not very useful when you are asking how one performs.

Four ways the field differs
1. Receptor balance. Three receptors do not mean equal activity at each. How a molecule weights its three targets is a design choice, and it is often disclosed only in part, and for several challengers not at all. For the best-documented example, see the retatrutide entry.
2. Delivery. Retatrutide and UBT251 are weekly injections in the trials. ASC37 is designed as a monthly depot, covered in PB’s ASC37 post. Lilly’s LY4086940 is an oral candidate, with its public record laid out in the LY4086940 timeline. MWN109 has both injection and tablet programs in the registry, and a 2025 conference abstract described it as a “dual-format” molecule tested in non-human primates.
3. Trial design. The numbers below come from very different setups.
| Candidate | Phase | Participants | Length | Setting |
|---|---|---|---|---|
| Retatrutide (TRIUMPH-1) | 3 | 2,339 adults with obesity, no diabetes | 80 weeks | Global, sponsor Eli Lilly |
| UBT251, obesity | 2 | 205 adults, no diabetes | 24 weeks | China |
| UBT251, type 2 diabetes | 2 | 211 adults, with a semaglutide 1 mg arm | 24 weeks | China |
| KAI-4729 / HRS-4729 | 1 | About a dozen on drug, per Kailera | 12 weeks | China |
4. Who wrote the paper. The UBT251 papers list employees of United Laboratories and Novo Nordisk among the authors. The retatrutide paper is funded by Eli Lilly with Lilly authors. That is normal for drug trials and worth knowing. It is one reason this page separates peer-reviewed results from company announcements.
The evidence ladder
| Candidate | What is public | Evidence class | Strength |
|---|---|---|---|
| Retatrutide | NEJM phase 3 paper, TRIUMPH-1 | Published human clinical trial (Tier 1), sponsor funded | Strongest in the field |
| UBT251 | Phase 1a/1b paper, two phase 2 papers (Cell Metabolism, Oct 2026) | Published human clinical trials (Tier 1), sponsor-affiliated authors | Solid but short and single-country |
| KAI-4729 / HRS-4729 | Kailera press release, May 27, 2026 | Company-reported, no paper found (Tier 2) | Early signal only |
| MWN109 | Registry records, a 2025 non-human primate abstract | Registered human trials without public results (Tier 2); animal (Tier 3) | No efficacy numbers found |
| BI 3034701 | Phase 2 registration, press note | Registered human trial, no results (Tier 2) | Nothing to weigh yet |
| ASC37, CT-G32 | Developer releases, animal data | Developer and preclinical (Tiers 3 and 4) | Premature for human claims |
| NBIP-1968 | Phase 1 single-dose study began Aug 2026 | Registered human trial, no results (Tier 2) | Nothing to weigh yet |
For the pages behind the bottom rows see UBT251, ASC37, CT-G32 and the NBIP-1968 entry.
Amounts and schedules reported in the trials
Figures in this section summarize amounts and schedules reported in published research or company announcements. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Candidate | Route reported | Amount reported | Frequency | Duration | Evidence class |
|---|---|---|---|---|---|
| Retatrutide, TRIUMPH-1 | Subcutaneous | 4 mg, 9 mg or 12 mg | Once weekly | 80 weeks | Published human clinical trial |
| UBT251, obesity phase 2 | Subcutaneous | 2 mg, 4 mg (starting at 0.5 mg or 1 mg) or 6 mg | Once weekly | 24 weeks | Published human clinical trial |
| UBT251, phase 1b | Subcutaneous | 1 mg, 3 mg or 6 mg | Once weekly | 12 weeks | Published human clinical trial |
| KAI-4729 / HRS-4729 | Injection | Escalated from 2 mg to 12 mg | Weekly | 12 weeks | Company reported |
| MWN109, BI 3034701, ASC37, CT-G32 | Not disclosed | Not consistently reported | Not consistently reported | Not consistently reported | Registry or preclinical only |
Units are in milligrams per administration. Nothing here converts animal amounts to human amounts, and none of it is guidance for any reader. The dose pages for retatrutide are on PB under retatrutide dosage.
How to read the headline numbers
Weight-loss figures only compare when population, length, analysis method and placebo response line up. They rarely do.
An example inside one drug. In TRIUMPH-1, the NEJM paper reports mean weight change of -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) against -3.9% on placebo, using a treatment-regimen estimand (everyone randomized, whatever they did afterward). Lilly’s earlier topline release quoted 28.3% for the same trial using an efficacy estimand (people who stayed on treatment). Both are real. They answer different questions. A review published in October 2026 in Pharmaceutics, with an evidence cutoff of September 11, still described the obesity trials as sponsor toplines, because the NEJM paper appeared on September 29. Evidence status in this field can change in weeks, so every claim on this page carries a date.
An example across drugs. UBT251 reported -19.7% to -13.6% at 24 weeks against -2.0% on placebo in Chinese adults without diabetes (Cell Metabolism, Oct 8, 2026). KAI-4729’s company-reported figure is up to 16% at 12 weeks against 5% on placebo. Retatrutide’s 80-week figures are above. None of these three numbers can be ranked against another. They differ in length, population, analysis and number of people. The abstracts for the UBT251 papers do not state which estimand was used, which is a detail to check in the full text.
Three questions help with any figure in this field:
- What was the placebo group’s result?
- Which estimand produced the number?
- How many people, for how long, and where?
The China and licensing story is about sequence
Several leading triple agonists come from China, and the pattern is worth reading carefully.

UBT251. United Biotechnology (part of The United Laboratories) licensed UBT251 to Novo Nordisk on March 24, 2025. Novo received worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan, with $200 million upfront and up to $1.8 billion in milestones plus tiered royalties (announcement via BioSpace). United Biotechnology kept the four territories it excluded.
The trial record then splits by geography:
- In China, the registry lists phase 3 trials with September 2026 start dates, including an obesity trial (NCT07648225, 600 people) and two type 2 diabetes trials, UNIGUIDE-1 against placebo (NCT07659574, 360 people) and UNIGUIDE-2 against semaglutide (NCT07653477, 956 people). Two sleep apnea phase 3 trials are listed as not yet recruiting.
- Outside China, Novo’s own phase 2 in overweight or obesity (NCT07395687, 333 people) is recruiting, with primary completion listed as January 14, 2027.
The practical reading: the drug is moving fastest where one population has been studied, while the global data that would support a worldwide approval are still being collected.
KAI-4729 / HRS-4729. Kailera Therapeutics in-licensed four assets from Hengrui, and Hengrui ran the phase 1 trial in China (BioPharma Dive). Hengrui is moving the drug into phase 2 in China, with registry entries for a type 2 diabetes phase 2 (comparing against mazdutide) and a fatty liver phase 2. Kailera says its own phase 1 outside China will report in 2027.
MWN109. Shanghai Minwei Biotechnology has registered a phase 1a, a phase 1b, two phase 2 trials, a tablet maintenance extension and a planned 760-person phase 3. One phase 2 (NCT07791654) enrolled 120 non-diabetic adults with overweight or obesity across three MWN109 arms and placebo for 24 weeks, started August 23, 2025 and is listed as completed on March 21, 2026, with a body-weight primary endpoint. No results are posted in the registry, and none were found in PubMed or in sponsor releases for this review.
A scientific caution. A licensing price reflects a company’s judgment under uncertainty. It is not evidence that a drug works, and a phase 3 start is not evidence that a phase 3 succeeded.
What would change the picture
- UBT251 phase 2 data from outside China (Novo’s trial, primary completion listed January 2027)
- Any peer-reviewed or conference report from Hengrui’s phase 2 for HRS-4729
- Efficacy data from MWN109’s completed phase 2
- Whether BI 3034701’s NPY2 route behaves like a glucagon-based triple in tolerability and lean mass
- Head-to-head data. The UBT251 type 2 diabetes phase 2 had a semaglutide 1 mg arm, and Hengrui has registered a mazdutide comparison. Neither is a head-to-head against retatrutide.
For readers interested in the lean-mass question that glucagon and amylin additions raise, see what happens to muscle on GLP-1 drugs. For a wider view of where these programs sit, the Weight Loss Atlas pipeline page tracks the obesity drug pipeline by company and stage.
Limits of this analysis
Pipeline trials change status monthly. Registry records can lag actual trial progress. This article relies on published papers, registry entries and company releases, and has not seen full-text methods for several candidates. It does not compare drugs head-to-head, and it does not suggest any person should take any of them. None of these drugs is approved. This page treats KAI-4729 and HRS-4729 as the same molecule, based on a poster link cited in secondary reporting; no sponsor statement confirming the match was found. See also the FDA peptide status guide, the compare tool and the GLP-1 and obesity peptides hub.
Frequently asked questions
What is a triple agonist?
A single drug molecule designed to switch on three hormone receptors. In obesity research the most common combination is GLP-1, GIP and glucagon, though not every “triple” uses that set.
Are all triple agonists the same?
No. They differ in receptors (BI 3034701 uses NPY2 in place of glucagon), delivery (weekly injection, monthly depot, oral), development stage and evidence.
Which triple agonists have peer-reviewed human results?
Retatrutide (phase 3, NEJM, Sept 29, 2026) and UBT251 (a phase 1a/1b paper and two phase 2 papers, Sept to Oct 2026). Others rely on company reports or registry entries.
Can I compare UBT251 and retatrutide weight loss?
Not fairly. The trials differ in length (24 versus 80 weeks), size (205 versus 2,339), population and analysis method.
Are triple agonists approved?
No triple agonist is approved anywhere as of November 12, 2026.
Why do licensing deals matter?
They show where companies see promise and who holds rights in which regions. They do not show that a drug works. One recent example outside the triple agonist class is ribupatide, a dual GLP-1 and GIP agonist that Hengrui licensed to Kailera for markets outside Greater China; its phase 3 paper in JAMA is analyzed here.
Where can I read the trial amounts?
The amounts reported in trials are in the table above, with a dedicated page for retatrutide dosage. These document research, not recommendations.
Bottom line
“Triple agonist” names a design idea, not a quality tier. Retatrutide has the only phase 3 paper, with a 25.0% mean weight reduction at 80 weeks at the highest dose in the treatment-regimen analysis. UBT251 has the next strongest record, with peer-reviewed phase 2 data and Chinese phase 3 trials running. Most others have an early company announcement or a registry entry. The honest way to read this field is by evidence class, not by headline percentage, and by date.
Sources
| Source | Organization / authors | Publication | Date | Category |
|---|---|---|---|---|
| Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity | Jastreboff AM et al., Eli Lilly funded | N Engl J Med 395(18):1781-1793 | Sept 29, 2026 | Published human clinical trial |
| UBT251 in adults with overweight or obesity: phase 2 | Zhou Z et al. | Cell Metab | Oct 8, 2026 | Published human clinical trial |
| UBT251 in adults with type 2 diabetes: phase 2 | Zhou Z et al. | Cell Metab | Oct 26, 2026 | Published human clinical trial |
| UBT251 phase 1a/1b | Yang G-P et al. | Diabetes Obes Metab 28(12):11217-11229 | Sept 8, 2026 | Published human clinical trial |
| Retatrutide as a unimolecular GIP/GLP-1/glucagon tri-agonist (review) | Mateescu D-M et al. | Pharmaceutics 18(10) | Oct 9, 2026 | Narrative review |
| United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251 | United Laboratories, Novo Nordisk | Press release via BioSpace | Mar 24, 2025 | Company announcement |
| Kailera triple agonist phase 1 data | BioPharma Dive | News report on Kailera release | May 27, 2026 | News, company-reported data |
| BI 3034701 phase 2 start | BioPharm International | News | Jul 16, 2026 | News |
| MWN109 non-human primate abstract 1967-LB | ADA Scientific Sessions abstract | Diabetes 74(Suppl 1) | 2025 | Preclinical abstract |
| ClinicalTrials.gov: NCT07648225, NCT07659574, NCT07653477, NCT07395687, NCT06762600, NCT07660848, NCT07843862, NCT07787728, NCT07791654, NCT07778693, NCT07662122 | NIH/NLM | Registry | Read Nov 12, 2026 | Government registry |
| Reta’s Rivals Are Waiting in the Wings | Krysia | Substack | Oct 24, 2026 | Independent investigation, credited as the 13-candidate survey that prompted this analysis |
| Retatrutide: will Big Pharma repeat history? | Peptides Weekly | Substack | Oct to Nov 2026 | Independent commentary |
Update history: November 12, 2026, first version.